ISSN: 1546-962X
CODEN: JAIOAD
Published Online: 3 January 2005
Page Count: 10

The Role of TGA-DTA in the Initial Evaluation of the Solid State Forms for Pharmaceutical New Chemical Entities, Part 1: Evaluation of Pure Forms

Redman-Furey, NL
Principal Scientist, P&G Pharmaceuticals, Inc., Norwich, New York,

Dicks, ML
Principal Researcher, P&G Pharmaceuticals, Inc., Norwich, New York,

Godlweski, J
Principal Scientist, P&G Pharmaceuticals, Inc., Norwich, New York,

Vaughn, DC
Senior Researcher, P&G Pharmaceuticals, Inc., Norwich, New York,

Collins, WJ
Senior Researcher, P&G Pharmaceuticals, Inc., Norwich, New York,

(Received 24 May 2004; accepted 15 September 2004)

Abstract

TGA-DTA plays a central role in the strategy outlined for early evaluation of the solid state forms available to pharmaceutical new chemical entities. At this early stage of development, compound and time are typically at a premium, so a successful strategy requires making the best possible use of the materials and time available. In addition, because of time and compound limitations, the goal of a solid state investigation is focused upon early stage objectives rather than development of a complete understanding of all available solid state forms. The TGA-DTA is well suited to addressing these needs.

Keywords:
TGA, DTA, hydrate, thermal analysis, hygroscopicity, pharmaceutical

Paper ID: JAI12791
DOI: 10.1520/JAI12791
ASTM International is a member of CrossRef.